Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2829 - Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC)

Date

11 Sep 2017

Session

Poster display session

Topics

Soft Tissue Sarcomas

Presenters

Angela Pang

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

A. Pang1, R. Ngan2, S.H. Tan3, T. Hirose4, M. Endo5, M. Farid6, W.L. Goh6, H.H. Loong7, S. Mingmalairak8, C. Chang9, S. Teo10, M.M. Maw11, A.K.C. Leung2, J.C. Chan12, M.E. Puhaindran13, A. Kawai4, T.W. Chen14, R. Quek6, V. Sriuranpong8

Author affiliations

  • 1 Department Of Haematology-oncology, National University Cancer Institute, National University Health System, 119074 - Singapore/SG
  • 2 Department Of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong/HK
  • 3 Division Of Clinical Trials And Epidemiological Sciences, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 4 Division Of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo/JP
  • 5 Department Of Orthopaedic Surgery, Kyushu University, Fukuoka/JP
  • 6 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 7 Department Of Clinical Oncology, The Chinese University of Hong Kong, 00000 - Hong Kong/HK
  • 8 Division Of Medical Oncology, Department Of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok/TH
  • 9 Department Of Cancer Administration And Coordination Center, National Taiwan University Hospital, Taipei/TW
  • 10 Department Of Haematology-oncology, National University Cancer Institute, National University Health System, Singapore/SG
  • 11 Medical Oncology Unit, University of Medicine 1, Yangon, Yangon/MM
  • 12 Department Of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR/HK
  • 13 Department Of Hand And Reconstructive Microsurgery, National University Hospital, Singapore/SG
  • 14 Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW
More

Resources

Abstract 2829

Background

We previously reported on the real world treatment and outcomes of 423 angiosarcoma pts in Asia. In this current report, we focus on the 173 pts with V-AS and evaluate the treatment patterns and prognostic factors associated with this disease subset.

Methods

This is a retrospective chart review of V-AS pts seen at 8 Asian academic study sites. Survival analysis is measured from date of presentation to the study site.

Results

Median study follow-up was 8.7 mths. Median age 52 yrs; 86% of pts presented with primary disease to study site. 42% (n = 73) had localized disease and 56% (n = 97) had locally advanced/unresectable or metastatic disease; disease status was unknown for 3 pts. Distribution of primary site as follows, liver (n = 38, 22%), cardiovascular system (n = 30, 17%), breast (n = 25, 14%), spleen (n = 18, 10%) and others (n = 62, 36%) from a myriad of organ systems each representing  3 lines of treatment respectively. The most common first line chemotherapy used was paclitaxel (53%) followed by liposomal doxorubicin (18%). Median OS was 11.9 mths in the overall V-AS cohort, with median OS 29.2 mths and 6.3 mths in the localized and advanced/unresectable cohort respectively. In the univariate analysis of pts with unresectable/metastatic disease, only ECOG was associated with OS.

Conclusions

This study highlights the heterogeneity and treatment challenges of visceral angiosarcoma. Overall prognosis is poor, in particular in pts with advanced/unresectable disease.

Clinical trial identification

NA

Legal entity responsible for the study

National Cancer Centre Singapore

Funding

None

Disclosure

R. Quek: Grants/research support: Novartis, Pfizer, Janssen, Bayer and Eisai. Honoraria/consultation fees: Novartis, Bayer, BMS, Merck, Roche and Eisai. Participation in a company sponsored speaker\'s bureau: Novartis, Bayer, Merck and Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.